Prognostic and predictive value of endothelial dysfunction biomarkers in sepsis-associated acute kidney injury: risk-stratified analysis from a prospective observational cohort of pediatric septic shock.
Biomarkers
Endothelial dysfunction
Precision medicine
Sepsis
Sepsis-associated acute kidney injury
Septic shock
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
03 07 2023
03 07 2023
Historique:
received:
10
05
2023
accepted:
28
06
2023
medline:
5
7
2023
pubmed:
4
7
2023
entrez:
3
7
2023
Statut:
epublish
Résumé
Sepsis-associated acute kidney injury (SA-AKI) is associated with high morbidity, with no current therapies available beyond continuous renal replacement therapy (CRRT). Systemic inflammation and endothelial dysfunction are key drivers of SA-AKI. We sought to measure differences between endothelial dysfunction markers among children with and without SA-AKI, test whether this association varied across inflammatory biomarker-based risk strata, and develop prediction models to identify those at highest risk of SA-AKI. Secondary analyses of prospective observational cohort of pediatric septic shock. Primary outcome of interest was the presence of ≥ Stage II KDIGO SA-AKI on day 3 based on serum creatinine (D3 SA-AKI SCr). Biomarkers including those prospectively validated to predict pediatric sepsis mortality (PERSEVERE-II) were measured in Day 1 (D1) serum. Multivariable regression was used to test the independent association between endothelial markers and D3 SA-AKI SCr. We conducted risk-stratified analyses and developed prediction models using Classification and Regression Tree (CART), to estimate risk of D3 SA-AKI among prespecified subgroups based on PERSEVERE-II risk. A total of 414 patients were included in the derivation cohort. Patients with D3 SA-AKI SCr had worse clinical outcomes including 28-day mortality and need for CRRT. Serum soluble thrombomodulin (sTM), Angiopoietin-2 (Angpt-2), and Tie-2 were independently associated with D3 SA-AKI SCr. Further, Tie-2 and Angpt-2/Tie-2 ratios were influenced by the interaction between D3 SA-AKI SCr and risk strata. Logistic regression demonstrated models predictive of D3 SA-AKI risk performed optimally among patients with high- or intermediate-PERSEVERE-II risk strata. A 6 terminal node CART model restricted to this subgroup of patients had an area under the receiver operating characteristic curve (AUROC) 0.90 and 0.77 upon tenfold cross-validation in the derivation cohort to distinguish those with and without D3 SA-AKI SCr and high specificity. The newly derived model performed modestly in a unique set of patients (n = 224), 84 of whom were deemed high- or intermediate-PERSEVERE-II risk, to distinguish those patients with high versus low risk of D3 SA-AKI SCr. Endothelial dysfunction biomarkers are independently associated with risk of severe SA-AKI. Pending validation, incorporation of endothelial biomarkers may facilitate prognostic and predictive enrichment for selection of therapeutics in future clinical trials among critically ill children.
Sections du résumé
BACKGROUND
Sepsis-associated acute kidney injury (SA-AKI) is associated with high morbidity, with no current therapies available beyond continuous renal replacement therapy (CRRT). Systemic inflammation and endothelial dysfunction are key drivers of SA-AKI. We sought to measure differences between endothelial dysfunction markers among children with and without SA-AKI, test whether this association varied across inflammatory biomarker-based risk strata, and develop prediction models to identify those at highest risk of SA-AKI.
METHODS
Secondary analyses of prospective observational cohort of pediatric septic shock. Primary outcome of interest was the presence of ≥ Stage II KDIGO SA-AKI on day 3 based on serum creatinine (D3 SA-AKI SCr). Biomarkers including those prospectively validated to predict pediatric sepsis mortality (PERSEVERE-II) were measured in Day 1 (D1) serum. Multivariable regression was used to test the independent association between endothelial markers and D3 SA-AKI SCr. We conducted risk-stratified analyses and developed prediction models using Classification and Regression Tree (CART), to estimate risk of D3 SA-AKI among prespecified subgroups based on PERSEVERE-II risk.
RESULTS
A total of 414 patients were included in the derivation cohort. Patients with D3 SA-AKI SCr had worse clinical outcomes including 28-day mortality and need for CRRT. Serum soluble thrombomodulin (sTM), Angiopoietin-2 (Angpt-2), and Tie-2 were independently associated with D3 SA-AKI SCr. Further, Tie-2 and Angpt-2/Tie-2 ratios were influenced by the interaction between D3 SA-AKI SCr and risk strata. Logistic regression demonstrated models predictive of D3 SA-AKI risk performed optimally among patients with high- or intermediate-PERSEVERE-II risk strata. A 6 terminal node CART model restricted to this subgroup of patients had an area under the receiver operating characteristic curve (AUROC) 0.90 and 0.77 upon tenfold cross-validation in the derivation cohort to distinguish those with and without D3 SA-AKI SCr and high specificity. The newly derived model performed modestly in a unique set of patients (n = 224), 84 of whom were deemed high- or intermediate-PERSEVERE-II risk, to distinguish those patients with high versus low risk of D3 SA-AKI SCr.
CONCLUSIONS
Endothelial dysfunction biomarkers are independently associated with risk of severe SA-AKI. Pending validation, incorporation of endothelial biomarkers may facilitate prognostic and predictive enrichment for selection of therapeutics in future clinical trials among critically ill children.
Identifiants
pubmed: 37400882
doi: 10.1186/s13054-023-04554-y
pii: 10.1186/s13054-023-04554-y
pmc: PMC10318688
doi:
Substances chimiques
Biomarkers
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
260Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK119463
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR001426
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM126943
Pays : United States
Organisme : NIH HHS
ID : KL2TR001426
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Crit Care. 2022 Jul 11;26(1):210
pubmed: 35818064
Crit Care Med. 2016 Nov;44(11):2010-2017
pubmed: 27513537
N Engl J Med. 2017 Jan 5;376(1):11-20
pubmed: 27959707
Pediatrics. 2010 May;125(5):1031-41
pubmed: 20421258
Crit Care. 2017 Aug 25;21(1):229
pubmed: 28841902
Am J Respir Crit Care Med. 2020 Apr 1;201(7):848-855
pubmed: 31916857
Semin Nephrol. 2015 Jan;35(1):2-11
pubmed: 25795495
Kidney Int. 2019 Nov;96(5):1083-1099
pubmed: 31443997
Clin J Am Soc Nephrol. 2008 Jul;3(4):948-54
pubmed: 18417742
Crit Care. 2020 Apr 15;24(1):150
pubmed: 32295614
Nat Rev Nephrol. 2017 Apr;13(4):241-257
pubmed: 28239173
Ann Intensive Care. 2019 Sep 11;9(1):103
pubmed: 31512003
Clin J Am Soc Nephrol. 2015 Aug 7;10(8):1324-31
pubmed: 26195505
Am J Respir Crit Care Med. 2019 Apr 1;199(7):863-872
pubmed: 30334632
JAMA. 2005 Aug 17;294(7):813-8
pubmed: 16106006
Sci Transl Med. 2019 Nov 13;11(518):
pubmed: 31723040
Am J Respir Crit Care Med. 2020 Aug 1;202(3):361-370
pubmed: 32101446
Intensive Care Med. 2009 May;35(5):871-81
pubmed: 19066848
Pediatr Crit Care Med. 2020 Sep;21(9):e686-e695
pubmed: 32569242
J Pediatr. 1997 Oct;131(4):575-81
pubmed: 9386662
Nat Rev Nephrol. 2020 Jan;16(1):20-31
pubmed: 31511662
Sci Rep. 2018 Jan 11;8(1):505
pubmed: 29323190
J Intensive Care. 2020 Dec 11;8(1):94
pubmed: 33308326
Pediatr Crit Care Med. 2005 Jan;6(1):2-8
pubmed: 15636651
Intensive Care Med. 2020 May;46(5):1050-1051
pubmed: 32047942
Crit Care Med. 2016 Dec;44(12):2241-2250
pubmed: 27513354
Crit Care Med. 2020 Oct;48(10):1513-1520
pubmed: 32769621
Crit Care. 2021 Feb 4;25(1):48
pubmed: 33541396
JAMA. 2019 May 28;321(20):1993-2002
pubmed: 31104069
Crit Care. 2016 Jul 03;20(1):207
pubmed: 27372077